Positive Blood Culture Removal Time Significantly Decreases Processing Time
|
By LabMedica International staff writers Posted on 18 Feb 2015 |
Timely processing of blood cultures with positive results, including Gram staining and notification of clinicians, is a critical function of the clinical microbiology laboratory.
Although empiric administration of antibiotics is critical, targeted therapy based on actionable data from the clinical microbiology laboratory must be implemented as soon as the data are available as inadequate antimicrobial treatment of bloodstream infections is associated with significantly increased mortality and, in surviving patients, increased hospital length of stay.
Scientists at the Houston Methodist Hospital (TX, USA) performed a retrospective analysis of positive blood culture processing times. Data for specimens collected seven months before and seven months after an in-service meeting were retrieved and analyzed. In some instances, no organisms were seen on initial Gram stain after a positive alert. In those cases, the culture bottles were returned to the automated blood culture system BACTEC FX instrument (BD Diagnostics, Sparks, MD, USA) for further incubation. As the Epicenter software does not log the initial removal, the positive-to-removal (PR) time was erroneously prolonged, and these samples were excluded from the analysis.
Before the in-service meeting, the average PR time for 5,057 samples was 38 minutes. They discovered unexpectedly that only 51.8% (2,617 of 5,057) of the positive blood cultures were removed in less than 10 minutes. After the in-service meeting, for 5,293 samples, the average PR time improved to eight minutes, the aggregate time also improved, and 84.5% (4,470 of 5,293) of the positive blood cultures were removed in less than 10 minutes. These improvements reduced the time to telephone notification of the Gram stain results to a caregiver by 46.7% (from 105 minutes to 56 minutes).
The authors concluded improvement of sepsis outcomes and costs requires rapid generation of actionable data from the clinical microbiology laboratory. Vigilant monitoring of parameters such as the PR time and meticulous identification of barriers to rapid pathogen identification has the potential to continue to decrease pathogen reporting time, decrease health care costs, and decrease morbidity and mortality associated with bloodstream infections. The study was published in the February 2015 issue of the Archives of Pathology & Laboratory Medicine.
Related Links:
Houston Methodist Hospital
BD Diagnostics
Although empiric administration of antibiotics is critical, targeted therapy based on actionable data from the clinical microbiology laboratory must be implemented as soon as the data are available as inadequate antimicrobial treatment of bloodstream infections is associated with significantly increased mortality and, in surviving patients, increased hospital length of stay.
Scientists at the Houston Methodist Hospital (TX, USA) performed a retrospective analysis of positive blood culture processing times. Data for specimens collected seven months before and seven months after an in-service meeting were retrieved and analyzed. In some instances, no organisms were seen on initial Gram stain after a positive alert. In those cases, the culture bottles were returned to the automated blood culture system BACTEC FX instrument (BD Diagnostics, Sparks, MD, USA) for further incubation. As the Epicenter software does not log the initial removal, the positive-to-removal (PR) time was erroneously prolonged, and these samples were excluded from the analysis.
Before the in-service meeting, the average PR time for 5,057 samples was 38 minutes. They discovered unexpectedly that only 51.8% (2,617 of 5,057) of the positive blood cultures were removed in less than 10 minutes. After the in-service meeting, for 5,293 samples, the average PR time improved to eight minutes, the aggregate time also improved, and 84.5% (4,470 of 5,293) of the positive blood cultures were removed in less than 10 minutes. These improvements reduced the time to telephone notification of the Gram stain results to a caregiver by 46.7% (from 105 minutes to 56 minutes).
The authors concluded improvement of sepsis outcomes and costs requires rapid generation of actionable data from the clinical microbiology laboratory. Vigilant monitoring of parameters such as the PR time and meticulous identification of barriers to rapid pathogen identification has the potential to continue to decrease pathogen reporting time, decrease health care costs, and decrease morbidity and mortality associated with bloodstream infections. The study was published in the February 2015 issue of the Archives of Pathology & Laboratory Medicine.
Related Links:
Houston Methodist Hospital
BD Diagnostics
Read the full article by registering today, it's FREE!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
- Free digital version edition of LabMedica International sent by email on regular basis
- Free print version of LabMedica International magazine (available only outside USA and Canada).
- Free and unlimited access to back issues of LabMedica International in digital format
- Free LabMedica International Newsletter sent every week containing the latest news
- Free breaking news sent via email
- Free access to Events Calendar
- Free access to LinkXpress new product services
- REGISTRATION IS FREE AND EASY!
Sign in: Registered website members
Sign in: Registered magazine subscribers
Latest Microbiology News
- Three-Test Panel Launched for Detection of Liver Fluke Infections
- Rapid Test Promises Faster Answers for Drug-Resistant Infections
- CRISPR-Based Technology Neutralizes Antibiotic-Resistant Bacteria
- Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
- AI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
- New Test Measures How Effectively Antibiotics Kill Bacteria
- New Antimicrobial Stewardship Standards for TB Care to Optimize Diagnostics
- New UTI Diagnosis Method Delivers Antibiotic Resistance Results 24 Hours Earlier
- Breakthroughs in Microbial Analysis to Enhance Disease Prediction
- Blood-Based Diagnostic Method Could Identify Pediatric LRTIs
- Rapid Diagnostic Test Matches Gold Standard for Sepsis Detection
- Rapid POC Tuberculosis Test Provides Results Within 15 Minutes
- Rapid Assay Identifies Bloodstream Infection Pathogens Directly from Patient Samples
- Blood-Based Molecular Signatures to Enable Rapid EPTB Diagnosis
- 15-Minute Blood Test Diagnoses Life-Threatening Infections in Children
- High-Throughput Enteric Panels Detect Multiple GI Bacterial Infections from Single Stool Swab Sample
Channels
Clinical Chemistry
view channel
Simple Blood Test Offers New Path to Alzheimer’s Assessment in Primary Care
Timely evaluation of cognitive symptoms in primary care is often limited by restricted access to specialized diagnostics and invasive confirmatory procedures. Clinicians need accessible tools to determine... Read more
Existing Hospital Analyzers Can Identify Fake Liquid Medical Products
Counterfeit and substandard medicines remain a serious global health threat, with World Health Organization estimates suggesting that 10.5% of medicines in low- and middle-income countries are either fake... Read moreMolecular Diagnostics
view channel
Genetic Test Aids Early Detection and Improved Treatment for Cancers
Lynch syndrome is a hereditary genetic condition that significantly increases the risk of several cancers, including those of the bowel and urinary tract. Urinary tract cancers—affecting the kidney, bladder,... Read more
New Genome Sequencing Technique Measures Epstein-Barr Virus in Blood
The Epstein–Barr virus (EBV) infects up to 95% of adults worldwide and remains in the body for life. While usually kept under control, the virus is linked to cancers such as Hodgkin’s lymphoma and autoimmune... Read moreHematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read moreImmunology
view channel
New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer
Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read moreBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read morePathology
view channel
AI-Powered 3D Scanning System Speeds Cancer Screening
Cytology remains a cornerstone of cancer detection, requiring specialists to examine bodily fluids and cells under a microscope. This labor-intensive process involves inspecting up to one million cells... Read more
Single Sample Classifier Predicts Cancer-Associated Fibroblast Subtypes in Patient Samples
Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, in part because of its dense tumor microenvironment that influences how tumors grow and respond to treatment.... Read more
New AI-Driven Platform Standardizes Tuberculosis Smear Microscopy Workflow
Sputum smear microscopy remains central to tuberculosis treatment monitoring and follow-up, particularly in high‑burden settings where serial testing is routine. Yet consistent, repeatable bacillary assessment... Read more
AI Tool Uses Blood Biomarkers to Predict Transplant Complications Before Symptoms Appear
Stem cell and bone marrow transplants can be lifesaving, but serious complications may arise months after patients leave the hospital. One of the most dangerous is chronic graft-versus-host disease, in... Read moreTechnology
view channel
Blood Test “Clocks” Predict Start of Alzheimer’s Symptoms
More than 7 million Americans live with Alzheimer’s disease, and related health and long-term care costs are projected to reach nearly USD 400 billion in 2025. The disease has no cure, and symptoms often... Read more
AI-Powered Biomarker Predicts Liver Cancer Risk
Liver cancer, or hepatocellular carcinoma, causes more than 800,000 deaths worldwide each year and often goes undetected until late stages. Even after treatment, recurrence rates reach 70% to 80%, contributing... Read more
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreIndustry
view channel
QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio
QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more








